Skip to main content
SpringerLink
Log in
Book cover

Intraocular Inflammation pp 385–397Cite as

New Drugs

  • Chapter

  • 164 Accesses

Abstract

Rituximab is a chimeric murine/human monoclonal antibody that targets CD20 peripheral B cells. It is structured from murine antihuman CD20 (Fab domain) that binds to the CD20 antigen on B lymphocytes, while the Fc domain (from human IgG1) binds complement and promotes cellular cytotoxicity.

Keywords

  • Juvenile Idiopathic Arthritis
  • Anterior Uveitis
  • Sjogren Syndrome
  • Uveitis Patient
  • Intraocular Lymphoma

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (Canada)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   309.00
Price excludes VAT (Canada)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   399.00
Price excludes VAT (Canada)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

Rituximab

  1. Ahmadi-Simab K, Lamprecht P, Nolle B et al (2005) Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis 64:1087–1088

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  2. Aries PM, Hellmich B, Voswinkel J et al (2006) Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 65:853–858

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  3. Brihaye B, Aouba A, Pagnoux C et al (2007) Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener’s granulomatosis: a study on 8 patients. Clin Exp Rheumatol 25:S23–S27

    CAS  PubMed  Google Scholar 

  4. Bubien JK, Zhou LJ, Bell PD et al (1993) Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 121:1121–1132

    CrossRef  CAS  PubMed  Google Scholar 

  5. Chauhan S, Kamal A, Thompson RN et al (2009) Rituximab for treatment of scleritis associated with rheumatoid arthritis. Br J Ophthalmol 93:984–985

    CrossRef  CAS  PubMed  Google Scholar 

  6. Cheung CM, Murray PI, Savage CO (2005) Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 89:1542

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  7. Cohen SB, Emery P, Greenwald MW et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806

    CrossRef  CAS  PubMed  Google Scholar 

  8. Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246–252

    CrossRef  PubMed  Google Scholar 

  9. Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M (2011) Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect 1:177–180

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  10. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    CrossRef  CAS  PubMed  Google Scholar 

  11. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 54:1390–1400

    CrossRef  CAS  PubMed  Google Scholar 

  12. Freidlin J, Wong IG, Acharya N (2007) Rituximab treatment for peripheral ulcerative keratitis associated with Wegener’s granulomatosis. Br J Ophthalmol 91:1414

    CrossRef  PubMed Central  PubMed  Google Scholar 

  13. Gea-Banacloche JC (2010) Rituximab-associated infections. Semin Hematol 47:187–198

    CrossRef  CAS  PubMed  Google Scholar 

  14. Golay JT, Clark EA, Beverley PC (1985) The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 135:3795–3801

    CAS  PubMed  Google Scholar 

  15. Hansen A, Odendahl M, Reiter K et al (2002) Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren’s syndrome. Arthritis Rheum 46:2160–2171

    CrossRef  CAS  PubMed  Google Scholar 

  16. Heiligenhaus A, Miserocchi E, Heinz C et al (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 50:1390–1394

    CrossRef  CAS  Google Scholar 

  17. Huerva V, Sanchez MC, Traveset A et al (2010) Rituximab for peripheral ulcerative keratitis with wegener granulomatosis. Cornea 29:708–710

    PubMed  Google Scholar 

  18. Iaccheri B, Androudi S, Bocci EB et al (2010) Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 18:223–225

    CrossRef  CAS  PubMed  Google Scholar 

  19. Keogh KA, Wylan ME, Stone JH et al (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52:262–268

    CrossRef  PubMed  Google Scholar 

  20. Keogh KA, Ytterberg SR, Fervenza FC et al (2006) Rituximab for refractory Wegener’s granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 173:180–187

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  21. Kurz PA, Suhler EB, Choi D et al (2009) Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol 93:546–548

    CrossRef  CAS  PubMed  Google Scholar 

  22. Leandro MJ, Cambridge G, Ehrenstein MR et al (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613–620

    CrossRef  CAS  PubMed  Google Scholar 

  23. Lovric S, Erdbruegger U, Kumpers P et al (2009) Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 24:179–185

    CrossRef  CAS  PubMed  Google Scholar 

  24. Miserocchi E, Pontikaki I, Modorati G et al (2011) Rituximab for uveitis. Ophthalmology 118:223–224

    CrossRef  PubMed  Google Scholar 

  25. Omdal R, Wildhagen K, Hansen T et al (2005) Anti-CD20 therapy of treatment-resistant Wegener’s granulomatosis: favourable but temporary response. Scand J Rheumatol 34:229–232

    CrossRef  CAS  PubMed  Google Scholar 

  26. Onal S, Kazokoglu H, Koc A et al (2008) Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm 16:230–232

    CrossRef  CAS  PubMed  Google Scholar 

  27. Parikh JG, Tawansy KA, Rao NA (2008) Immunohistochemical study of chronic nongranulomatous anterior uveitis in juvenile idiopathic arthritis. Ophthalmology 115:1833–1836

    CrossRef  PubMed  Google Scholar 

  28. Pe‘er J, Hochberg FH, Foster CS (2009) Clinical review: treatment of vitreoretinal lymphoma. Ocul Immunol Inflamm 17:299–306

    CrossRef  PubMed  Google Scholar 

  29. Ramos-Casals M, Tzioufas AG, Stone JH et al (2010) Treatment of primary Sjögren syndrome: a systematic review. JAMA 304:452–460

    CrossRef  CAS  PubMed  Google Scholar 

  30. Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  31. Sadreddini S, Noshad H, Molaeefard M et al (2008) Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol 18:306–308

    CrossRef  CAS  PubMed  Google Scholar 

  32. Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22:7359–7368

    CrossRef  CAS  PubMed  Google Scholar 

  33. Specks U, Fervenza FC, McDonald TJ et al (2001) Response of Wegener’s granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 44:2836–2840

    CrossRef  CAS  PubMed  Google Scholar 

  34. Stashenko P, Nadler LM, Hardy R et al (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678–1685

    CAS  PubMed  Google Scholar 

  35. Stilling-Vinther MK, Pedersen BS (2011) Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol 90:e154–e155. doi:10.1111/j.1755-3768.2011.02127.x

    CrossRef  PubMed  Google Scholar 

  36. Stoll ML, Gotte AC (2008) Biological therapies for the treatment of juvenile idiopathic arthritis: lessons from the adult and pediatric experiences. Biologics 2:229–252

    PubMed Central  CAS  PubMed  Google Scholar 

  37. Tamura N, Matsudaira R, Hirashima M et al (2007) Two cases of refractory Wegener’s granulomatosis successfully treated with rituximab. Intern Med 46:409–414

    CrossRef  PubMed  Google Scholar 

  38. Tappeiner C, Heinz C, Specker C et al (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39:184–186

    CrossRef  CAS  PubMed  Google Scholar 

  39. Taylor SR, Salama AD, Joshi L et al (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 60:1540–1547

    CrossRef  PubMed  Google Scholar 

  40. Zapata LF, Agudelo LM, Paulo JD et al (2007) Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea 26:886–887

    CrossRef  PubMed  Google Scholar 

Daclizumab

  1. Beniaminovitz A, Itescu S, Lietz K et al (2000) Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 342:613–619

    CrossRef  CAS  PubMed  Google Scholar 

  2. Bhat P, Castañeda-Cervantes RA, Doctor PP et al (2009) Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 247:687–692

    CrossRef  CAS  PubMed  Google Scholar 

  3. Buggage RR, Levy-Clarke G, Sen HN et al (2007) A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet’s disease. Ocul Immunol Inflamm 15:63–70

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  4. Caspi RR, Roberge FG, McAllister CG et al (1986) T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol 136:928–933

    CAS  PubMed  Google Scholar 

  5. Feron EJ, Calder VL, Lightman SL (1992) Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. Curr Eye Res 11:167–172

    CrossRef  PubMed  Google Scholar 

  6. Guex-Crosier Y, Raber J, Chan CC et al (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158:452–458

    CAS  PubMed  Google Scholar 

  7. Hershberger RE, Starling RC, Eisen HJ et al (2005) Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 352:2705–2713

    CrossRef  CAS  PubMed  Google Scholar 

  8. Krueger JG, Walters IB, Miyazawa M et al (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43:448–458

    CrossRef  CAS  PubMed  Google Scholar 

  9. Lee SJ, Zahrieh D, Agura E et al (2004) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104:1559–1564

    CrossRef  CAS  PubMed  Google Scholar 

  10. Li Z, Lim WK, Mahesh SP et al (2005) Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis. J Immunol 174:5187–5191

    CrossRef  CAS  PubMed  Google Scholar 

  11. McDyer JF, Li Z, John S et al (2002) IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 169:2736–2746

    CrossRef  CAS  PubMed  Google Scholar 

  12. Nussenblatt RB, Fortin E, Schiffman R et al (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96:7462–7466

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  13. Nussenblatt RB, Thompson DJ, Li Z et al (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283–293

    CrossRef  CAS  PubMed  Google Scholar 

  14. Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112:764–770

    CrossRef  PubMed  Google Scholar 

  15. Okada AA, Sakai J, Usui M et al (1998) Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:111–120

    CrossRef  CAS  PubMed  Google Scholar 

  16. Papaliodis GN, Chu D, Foster CS (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110:786–789

    CrossRef  PubMed  Google Scholar 

  17. Sen HN, Levy-Clarke G, Faia LJ et al (2009) High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 148:696–703.e1

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  18. Sobrin L, Huang JJ, Christen W et al (2008) Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 126:186–191

    CrossRef  CAS  PubMed  Google Scholar 

  19. Vincenti F, Kirkman R, Light S et al (1998) Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 338:161–165

    CrossRef  CAS  PubMed  Google Scholar 

  20. Waldmann TA (2007) Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26:3699–3703

    CrossRef  CAS  PubMed  Google Scholar 

  21. Webster AC, Playford EG, Higgins G et al (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166–176

    CrossRef  CAS  PubMed  Google Scholar 

  22. Wroblewski K, Sen HN, Yeh S et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 46:322–328

    CrossRef  PubMed Central  PubMed  Google Scholar 

  23. Wynn D, Kaufman M, Montalban X et al (2010) Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 9:381–390

    CrossRef  CAS  PubMed  Google Scholar 

  24. Yeh S, Wroblewski K, Buggage R et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 31:91–97

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

Abatacept

  1. Angeles-Han S, Flynn T, Lehman T (2008) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis- a case report. J Rheumatol 35:1897–1898

    PubMed  Google Scholar 

  2. Elhai M, Deslandre CJ, Kahan A (2011) Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken) 63:307–308

    CrossRef  Google Scholar 

  3. Gartlehner G, Hansen RA, Jonas BL et al (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 27:67–76

    CrossRef  PubMed  Google Scholar 

  4. Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114–1123

    CrossRef  CAS  PubMed  Google Scholar 

  5. Kenawy N, Cleary G, Mewar D et al (2011) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 249:297–300

    CrossRef  PubMed  Google Scholar 

  6. Ruperto N, Lovell DJ, Quartier P et al (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 62:1792–1802

    CrossRef  CAS  PubMed  Google Scholar 

  7. Salliot C, Dougados M, Gossec L et al (2009) Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 68:25–32

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  8. Schiff M, Keiserman M, Codding C et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  9. Shao H, Woon MD, Nakamura S et al (2001) Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest Ophthalmol Vis Sci 42:2016–2021

    CAS  PubMed  Google Scholar 

  10. Silver PB, Hathcock KS, Chan CC et al (2000) Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 165:5041–5047

    CrossRef  CAS  PubMed  Google Scholar 

  11. Simon TA, Smitten AL, Franklin J et al (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68:1819–1826

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  12. Verwaerde C, Naud MC, Delanoye A et al (2003) Ocular transfer of retinal glial cells transduced ex vivo with adenovirus expressing viral IL-10 or CTLA4-Ig inhibits experimental autoimmune uveoretinitis. Gene Ther 10:1970–1981

    CrossRef  CAS  PubMed  Google Scholar 

  13. Weinblatt M, Schiff M, Goldman A et al (2007) Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann Rheum Dis 66:228–234

    CrossRef  PubMed Central  CAS  PubMed  Google Scholar 

  14. Yamada A, Salama AD, Sayegh MH (2002) The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 13:559–575

    CAS  PubMed  Google Scholar 

  15. Zulian F, Balzarin M, Falcini F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62:821–825

    CrossRef  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University Hospital of Larissa, University of Thessalia, Larissa, Greece

    Sofia Androudi MD, PhD & Anna Dastiridou MD, PhD

  2. Centre of Ophthalmology, University of Tuebingen, Schleichstr. 12, Tuebingen, 72076, Germany

    Manfred Zierhut MD

Authors
  1. Sofia Androudi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Dastiridou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manfred Zierhut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofia Androudi MD, PhD .

Editor information

Editors and Affiliations

  1. Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany

    Manfred Zierhut

  2. Biomedical Research Centre, Institute of Ophthalmology, Moorfields Eyes Hospital, Department of Medical Retina, UCL, London, United Kingdom

    Carlos Pavesio

  3. School of Medicine, Department of Ophthalmology, Hokkaido University Graduate, Sapporo, Hokkaido, Japan

    Shigeaki Ohno

  4. University of Belo Horizonte, Belo Horizonte, Brazil

    Fernando Orefice

  5. USC Eye Institute, University of Southern California, Los Angeles, California, USA

    Narsing A. Rao

Rights and permissions

Reprints and Permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Androudi, S., Dastiridou, A., Zierhut, M. (2016). New Drugs. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-75387-2_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-75385-8

  • Online ISBN: 978-3-540-75387-2

  • eBook Packages: MedicineMedicine (R0)

Search

Navigation